BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q2 Release

Company Overview - BioMarin Pharmaceutical (BMRN) is expected to report a year-over-year increase in earnings, with a projected quarterly earnings per share (EPS) of $0.56, reflecting a change of +3.7% [3] - Revenues are anticipated to reach $659.73 million, representing a 10.8% increase from the same quarter last year [4] Earnings Expectations - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [5] - The Most Accurate Estimate for BioMarin is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -13.67%, suggesting a bearish outlook from analysts [11] Historical Performance - In the last reported quarter, BioMarin exceeded expectations by posting earnings of $0.71 per share against an expected $0.60, achieving a surprise of +18.33% [14] - Over the past four quarters, the company has beaten consensus EPS estimates three times [15] Industry Comparison - Bristol Myers Squibb (BMY), another player in the biomedical industry, is expected to report an EPS of $1.64 for the same quarter, indicating a year-over-year decline of -6.3% [19] - Bristol Myers' revenues are projected to be $11.5 billion, up 2.5% from the previous year [19] - The consensus EPS estimate for Bristol Myers has been revised 1% lower in the last 30 days, resulting in an Earnings ESP of -0.15% [20]